Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

• Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
• Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
• As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N215206

Product 003
ATOGEPANT (QULIPTA) TABLET 60MG

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
003	8754096	07/19/2032	DS	DP	U-3534		10/26/2021
003	9499545	11/10/2031	DS	DP	U-3534		10/26/2021
003	9850246	03/13/2033	DS				10/26/2021
003	10117836	01/30/2035		DP			10/26/2021

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
003	I-909	04/17/2026
003	NCE	09/28/2026

 

 

View a list of all patent use codes
View a list of all exclusivity codes